MARKHAM, ON, Oct. 15, 2015 /CNW/ - The Canadian Urologic Oncology Group (CUOG), Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. (Astellas) are excited to announce the recipients of the second annual CUA-CUOG Astellas Research Grant Program.
In 2013, Astellas committed $450,000 over three years to initiate the program, which supports Canadian peer-reviewed research in uro-oncologic disorders, with the ultimate goal of improving patient care. This year, the CUOG Board of Directors received and reviewed seven high calibre research proposals for consideration. The 2015 CUA-Astellas Research Grant Program recipients are:
Vancouver Prostate Centre, UBC
"Evaluation of different test platforms for analysis of androgen receptor splice variants in the peripheral blood of patients with castration resistant prostate cancer"
Vancouver Prostate Centre, UBC
"Multi-target injectable paste as a novel treatment for localized prostate cancer – Preclinical modeling and optimization"
McMaster Institute of Urology - Department of Surgery (St. Joseph's Healthcare)
"Delineation of the biomarker value of aldehyde dehydrogenase 3A1 (ALDH3A1) in prostate cancer progression"
CHU de Québec Research Centre – Laval University
"Effect of Omega-3 Polyunsaturated Fatty Acid Dietary Supplementation on Prostate Cancer in Relation to the Fatty Acid Content of Diet"
"At Astellas, we are proud of our commitment to support the work of uro-oncology researchers, and their efforts to find new and innovative treatments for men battling prostate cancer," said Fran Paradiso-Hardy, Senior Director, Medical Affairs, Astellas Pharma Canada. "Congratulations to this year's recipients of the CUA-CUOG Astellas Research Grant Program."
Proposals for the 2016 CUA-CUOG Astellas Research Grant Program are now being accepted. The submission deadline is April 1st, 2016. Additional details regarding the eligibility criteria and application process can be found on the CUOG, CUA and Astellas websites:
About the Canadian Urological Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian urologists and to foster dedication of all members of the profession toward ensuring the highest possible standard of urologic care for Canadians.
The goals of the CUA are to:
- To foster and promote excellence in urologic practice through education and research.
- To provide leadership in promoting evidence based clinical practice through the development of practice guidelines.
- To foster and promote life-long learning by Canadian urologists through continuous professional development.
- To provide leadership in public education for urologic diseases.
- To represent Canadian urology in developing and fostering partnerships while maintaining the highest educational and ethical standards.
- To represent the Canadian urologic community in relationships with national and international medical societies.
More information about CUA can be found at www.cua.org
About the Canadian Urologic Oncology Group (CUOG)
The Canadian Urologic Oncology Group (CUOG) is a clinical research investigator network of leading academic and community based urologists, medical oncologists, and radiation oncologists, committed to furthering genitourinary (GU) cancer research in Canada.
CUOG pursues clinical trials in concert with the pharmaceutical industry to find medicines and cures to tackle urological disorders including, but not restricted to:
- Prostate cancer
- Bladder cancer
- Renal cancer
- Testicular cancer
More information about CUOG can be found at www.cuog.ca
About Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. In Canada, Astellas has an intense commercial focus on five therapeutic areas – Urology, Immunology, Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit the corporate website: www.astellas.ca
SOURCE Astellas Pharma Canada, Inc.
For further information: Tal Erdman, Canadian Urological Association, (514) 395-0376, email@example.com; Michelle Reale, Corporate Communications, Astellas Pharma Canada, Inc., (905) 946-5621, firstname.lastname@example.org